Rubius Therapeutics | Red Cell Therapeutics™️ | Home Rubius Therapeutics is realizing the power of red by creating red blood cells and transforming them into cellular medicines. Learn More.
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Total raised: $486M
Founded date: 2013
Investors 2
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 18.07.2018 | IPO | $241M | - |
| 01.03.2018 | - | $100M | - |
| 22.06.2017 | Series B | $120M | - |
| 09.12.2015 | - | $25M | - |
Mentions in press and media 24
| Date | Title | Description |
| 09.11.2021 | Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update | U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for RTX-224, Rubius’ Third Oncology Candidate Clinical Results Expected by Year-End or First Quarter 2022 in Phase 1 Trials of Single-Agent RTX-240 in Advan... |
| 23.02.2021 | Rubius Therapeutics : Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update | Reported Initial Key Takeaways in January 2021 Showing RTX-240 Stimulates Innate and Adaptive Immunity; Additional Clinical Results to be Presented in Early 2021 Escalated the Dose in RTX-240 Phase 1 Clinical Trial in Relapsed/Refractory Ac... |
| 30.06.2020 | Rubius marks milestone in PhI/II as CFO departs; Owkin closes $70M Series A; The Carlyle Group bets on Indian CDMO | → Some of the folks at Rubius Therapeutics weren’t too keen about our lede on the Takeda gene therapy story, which referenced their R&D mishaps. So they flagged another release out this morning, which highlights that the ... |
| 20.07.2018 | Rubius Therapeutics Announces Pricing of Initial Public Offering | - |
| 18.07.2018 | Rubius Therapeutics Raises $241M IPO | Cambridge-based biotech company Rubius Therapeutics has raised $241 million by selling 10.5 million shares in its initial public offering on Wednesday. Rubius had initially set the IPO for $200 million earlier this July, and its IPO share p... |
| 18.07.2018 | Rubius Therapeutics Raises $241M IPO | - |
| 02.03.2018 | Term Sheet — Friday, March 2 | VIRTUAL $$$ Good morning, Term Sheet readers. Paid Content See how A.I. can protect your enterprise From ExtraHop My colleague Robert Hackett discovered that Camp has been sketching out plans for a new cryptocurrency called “Eco” that aims ... |
| 01.03.2018 | Rubius Therapeutics Closes $100M Financing | Rubius Therapeutics, a Cambridge, MA-based biotechnology company creating a new class of cellular therapies, completed a $100m crossover financing. The company intends to use the proceeds to accelerate the development of its portfolio of RC... |
| 01.03.2018 | Rubius raises $100M in crossover round as cell therapies near human testing W h i t e p a p e r Weighing the Costs: | Rubius Therapeutics has pulled in another $100 million to fund the advance of its red blood cell therapies. The crossover round, which brings Rubius’ nine-month haul up to $220 million, comes as the Flagship Pioneering startup races to get ... |
| 01.03.2018 | A startup that's making 'superblood' to treat conditions like cancer just raised $100 million to get its treatments through key trials | Courtesy Rubius Rubius CEO Torben Straight Nissen Advertisement Rubius Therapeutics, a biotech developing red blood cell therapies, just raised $100 million. This is the second time the startup has raised money in the past year. In June 201... |
Show more